ChemoCentryx, a biopharmaceutical company specializing in orally-administered drugs and therapies, filed on Friday with the SEC to raise up to $69 million in an initial public offering. The company concentrates on providing pharmaceutical treatments for autoimmune diseases, inflammatory disorders, and cancer and currently has five drug candidates in clinical development. ChemoCentryx hopes for better luck this time around considering they filed for an IPO in 2008 but withdrew shortly after due to market conditions surounding the Global Financial Crisis. The Mountain View, CA-based company, which was founded in 1997 and booked $19 million in sales for the 12 months ended June 30, 2011, plans to list on the NASDAQ under the symbol CCXI. J.P. Morgan, Citi, and Cowen & Company are the lead underwriters on the deal. Terms and timing are still to come.
